#157990

CD47 Knock-out cell line

Cat. #157990

CD47 Knock-out cell line

Cat. #: 157990

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 10-12 weeks

Organism: Mouse

Tissue: Skin

Disease: Cancer

Model: Knock-Out

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: Binghamton University

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: CD47 Knock-out cell line
  • Cancer type filter: Skin cancer
  • Cancers detailed: Melanoma;Tumor microenvironment
  • Research fields: Cancer;Cell signaling and signal transduction;Drug development
  • Tool sub type: Continuous
  • Parental cell: B16F10
  • Organism: Mouse
  • Tissue: Skin
  • Disease: Cancer
  • Model: Knock-Out
  • Description: CRISPR/Cas9 edited B16F10 cell line designed to help uncover the impact of editing a cell surface protein (CD47), in a tumor microenvironment, and its use as a whole-cell vaccine. CRISPR edited B16F10 cells.
  • Production details: Cells were cultured in high glucose DMEM and supplemented with 10% v/v Fetal Bovine Serum (FBS)
  • Additional notes: CRISPR edited B16F10 cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can pro...
  • Recommended controls: B16F10 parental cells

Target Details

  • Target: CD47

Applications

  • Application notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to comp...

Handling

  • Format: Frozen
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice

References

  • Inducing Tumor Suppressive Microenvironments through Genome Edited CD47 -/- Syngeneic Cell Vaccination

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.